Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral dihydroergotamine (Ikaran LP 5 mg) for neurogenic orthostatic hypotension in dysautonomic patients
2006-005672-41Phase 2Active
- Sponsor
- Pierre Fabre Laboratories
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of dihydroergotamine in orthostatic hypotension (OH), sponsored by Pierre Fabre Laboratories. Primary endpoint: Change in systolic blood pressure during active standing test. Started Mar 2007; status: active.
02
Drugs
dihydroergotamine
03
Conditions
orthostatic hypotension (OH)
Beyond the preview
Go deeper on 2006-005672-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005672-41.